Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

[1]  Xuechu Zhen,et al.  Dopamine D1 receptor ligands: Where are we now and where are we going , 2009, Medicinal research reviews.

[2]  D. Nutt,et al.  Addiction: the clinical interface , 2008, British journal of pharmacology.

[3]  V. Watts,et al.  trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. , 2006, Journal of medicinal chemistry.

[4]  P. Jenner,et al.  What has been learnt from study of dopamine receptors in Parkinson's disease? , 2006, Pharmacology & therapeutics.

[5]  Sayaka Sekiya,et al.  Cyclization of aryl acyl radicals generated from S-(4-cyano)phenyl thiolesters by a nickel complex catalyzed electroreduction. , 2003, The Journal of organic chemistry.

[6]  K. Neve,et al.  Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. , 1996, Molecular pharmacology.

[7]  D E Nichols,et al.  Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. , 1996, Journal of medicinal chemistry.

[8]  R. Quirion,et al.  Dopamine D1, receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats , 1995, Neuroscience.

[9]  A. Lough,et al.  Preparation of 6,12-Imino-6H,12H-dibenzo[b,f]-1,5-dithiocins. , 1995 .

[10]  R. Mailman,et al.  Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine , 1995, Journal of medicinal chemistry.

[11]  P. Goldman-Rakic,et al.  Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys , 1994, Psychopharmacology.

[12]  R. Mailman,et al.  Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. , 1991, European journal of pharmacology.

[13]  R. Mailman,et al.  trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. , 1990, Journal of Medicinal Chemistry.

[14]  J. Clader,et al.  Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol. , 1989, Journal of medicinal chemistry.

[15]  S. Byrn,et al.  Effect of beta-alkyl substitution on D-1 dopamine agonist activity: absolute configuration of beta-methyldopamine. , 1987, Journal of medicinal chemistry.

[16]  R. Baldessarini,et al.  Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. , 2013, Chemical reviews.

[17]  D E Nichols,et al.  D1 dopamine receptors. , 2001, International review of neurobiology.

[18]  A. Barnett,et al.  Benzazepines: structure-activity relationships between D1 receptor blockade and selected pharmacological effects. , 1986, Advances in experimental medicine and biology.

[19]  S. Stahl,et al.  The dopamine hypothesis of schizophrenia: a review. , 1976, Schizophrenia bulletin.